We are delighted to announce that additional Series B funding has been agreed, with the members of Italian Angels for Growth and Club degli Investitori having committed funds of £0.6m ($1m). This financing will be used to further advance the candidates in NeoPhore’s drug discovery pipeline.
11.10.2021
Additional Series B funding announcement
More news
11.04.2024
NeoPhore presented preclinical data from our PMS2 program at the AACR Annual Meeting, San Diego, 5 - 10 April 2024.
The NeoPhore team attended the American Association for Cancer Research Annual Meeting in San Diego, 5 - 10 April 2024. In collaboration with The…
01.02.2024
NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline
NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline • Italian investors, NE…
11.10.2023
NeoPhore presented a first disclosure of NP1867 at AACR-NCI-EORTC Conference in Boston, USA
On Saturday October 14th, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston, USA NeoPhore presented a first…